...
首页> 外文期刊>World Journal of Surgical Oncology >Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients
【24h】

Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients

机译:高迁移率族box 1和血管内皮生长因子C的双阳性表达表明胃癌患者的预后较差

获取原文
           

摘要

Background Although many studies have indicated that high-mobility group box 1 protein (HMGB1) is associated with oncogenesis and a worse prognosis, the prognostic value of HMGB1 in gastric cancer (GC) remains unclear. In the present work, we aimed to evaluate the role of HMGB1 in GC and examined whether aberrant expression of both HMGB1 and vascular endothelial growth factor C (VEGF-C) increased the malignant potential of GC. Methods A total of 166 GC patients and 32 normal subjects were enrolled. HMGB1 and VEGF-C expression was detected by tissue microarrays (TMAs) and immunohistochemical staining. The correlation between HMGB1 and VEGF-C expression and their relationships with clinicopathological GC variables were examined. Univariate and multivariate analyses were performed using the Cox proportional hazard model to predict the factors related to the patients‘ overall survival rates. Results HMGB1 and VEGF-C expression were observed in 81 (48.80%) and 88 (53.01%) tumors, respectively, significantly higher than the rates among the corresponding controls. In addition, HMGB1 and VEGF-C expression were positively correlated (R2 = 0.972). HMGB1 expression was also closely associated with tumor size, pT stage, nodal status, metastasis status, TNM stage, and poor prognosis. Multivariate survival analysis indicated that patients with HMGB1 and VEGF-C coexpression had the worst prognoses and survival rates (hazard ratio, 2.78; log rank P Conclusions HMGB1 is commonly expressed in GC. Combined evaluation of HMGB1 and VEGF-C may serve as a valuable independent prognostic factor for GC patients.
机译:背景尽管许多研究表明,高迁移率的第1盒蛋白(HMGB1)与肿瘤发生和预后较差有关,但HMGB1在胃癌(GC)中的预后价值仍不清楚。在本工作中,我们旨在评估HMGB1在GC中的作用,并检查HMGB1和血管内皮生长因子C(VEGF-C)的异常表达是否增加了GC的恶性潜能。方法共纳入166例胃癌患者和32例正常人。 HMGB1和VEGF-C表达通过组织芯片(TMA)和免疫组织化学染色检测。研究了HMGB1和VEGF-C表达之间的相关性及其与临床病理GC变量的关系。使用Cox比例风险模型进行了单因素和多因素分析,以预测与患者总体生存率相关的因素。结果分别在81例(48.80%)和88例(53.01%)肿瘤中观察到HMGB1和VEGF-C的表达,明显高于相应对照组。另外,HMGB1和VEGF-C的表达呈正相关(R 2 = 0.972)。 HMGB1表达也与肿瘤大小,pT分期,淋巴结状态,转移状态,TNM分期和不良预后密切相关。多因素生存分析表明,HMGB1和VEGF-C共表达的患者预后和生存率最差(危险比2.78;对数秩P结论HMGB1通常在GC中表达。联合评估HMGB1和VEGF-C可能是有价值的GC患者的独立预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号